{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:20:10Z","timestamp":1787642410791,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca"},{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10549-026-08011-6","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:32:08Z","timestamp":1786537928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States"],"prefix":"10.1007","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6615-7076","authenticated-orcid":false,"given":"Filipa","family":"Lynce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"8011_CR1","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.Ccr-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429\u20134434. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-3045","journal-title":"Clin Cancer Res"},{"key":"8011_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109:1721\u20131728. https:\/\/doi.org\/10.1002\/cncr.22618","journal-title":"Cancer"},{"key":"8011_CR3","unstructured":"National Cancer Institute (2025) Cancer stat facts: female breast cancer subtypes. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html. Accessed November 21, 2025"},{"key":"8011_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/clep.S206949","volume":"11","author":"N Armstrong","year":"2019","unstructured":"Armstrong N, Ryder S, Forbes C, Ross J, Quek RG (2019) A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol 11:543\u2013561. https:\/\/doi.org\/10.2147\/clep.S206949","journal-title":"Clin Epidemiol"},{"key":"8011_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s1470-2045(17)30891-4","volume":"19","author":"ER Copson","year":"2018","unstructured":"Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG et al (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 19:169\u2013180. https:\/\/doi.org\/10.1016\/s1470-2045(17)30891-4","journal-title":"Lancet Oncol"},{"key":"8011_CR6","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/cam4.4566","volume":"11","author":"RM Layman","year":"2022","unstructured":"Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK (2022) Clinical outcomes and Oncotype DX Breast Recurrence Score\u00ae in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer Med 11:1474\u20131483. https:\/\/doi.org\/10.1002\/cam4.4566","journal-title":"Cancer Med"},{"key":"8011_CR7","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/ijc.32184","volume":"145","author":"M Deng","year":"2019","unstructured":"Deng M, Chen HH, Zhu X, Luo M, Zhang K, Xu CJ et al (2019) Prevalence and clinical outcomes of germline mutations in BRCA1\/2 and PALB2 genes in 2769 unselected breast cancer patients in China. Int J Cancer 145:1517\u20131528. https:\/\/doi.org\/10.1002\/ijc.32184","journal-title":"Int J Cancer"},{"key":"8011_CR8","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.3390\/cancers14133266","volume":"14","author":"P Pujol","year":"2022","unstructured":"Pujol P, Yauy K, Coffy A, Duforet-Frebourg N, Gabteni S, Daur\u00e8s JP et al (2022) Predominance of BRCA2 mutation and estrogen receptor positivity in unselected breast cancer with BRCA1 or BRCA2 mutation. Cancers (Basel) 14:3266. https:\/\/doi.org\/10.3390\/cancers14133266","journal-title":"Cancers (Basel)"},{"key":"8011_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10549-021-06446-7","volume":"192","author":"PH Lin","year":"2022","unstructured":"Lin PH, Chen SC, Tseng LM, Chang KJ, Huang AC, Cheng KC et al (2022) Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients. Breast Cancer Res Treat 192:629\u2013637. https:\/\/doi.org\/10.1007\/s10549-021-06446-7","journal-title":"Breast Cancer Res Treat"},{"key":"8011_CR10","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V.5.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 21, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way"},{"key":"8011_CR11","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147\u20132159. https:\/\/doi.org\/10.1056\/NEJMoa1612645","journal-title":"N Engl J Med"},{"key":"8011_CR12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41416-022-01711-y","volume":"126","author":"LW de Boo","year":"2022","unstructured":"de Boo LW, J\u00f3\u017awiak K, Joensuu H, Lindman H, Lauttia S, Opdam M et al (2022) Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. Br J Cancer 126:1401\u20131409. https:\/\/doi.org\/10.1038\/s41416-022-01711-y","journal-title":"Br J Cancer"},{"key":"8011_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41416-021-01597-2","volume":"126","author":"YD Guzm\u00e1n-Arocho","year":"2022","unstructured":"Guzm\u00e1n-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ et al (2022) Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer 126:302\u2013309. https:\/\/doi.org\/10.1038\/s41416-021-01597-2","journal-title":"Br J Cancer"},{"key":"8011_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JCO.19.00904","volume":"38","author":"A Lluch","year":"2020","unstructured":"Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J et al (2020) Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01). J Clin Oncol 38:203\u2013213. https:\/\/doi.org\/10.1200\/JCO.19.00904","journal-title":"J Clin Oncol"},{"key":"8011_CR15","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.21.00976","volume":"39","author":"IA Mayer","year":"2021","unstructured":"Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL et al (2021) Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol 39:2539\u20132551. https:\/\/doi.org\/10.1200\/JCO.21.00976","journal-title":"J Clin Oncol"},{"key":"8011_CR16","doi-asserted-by":"publisher","first-page":"e64268","DOI":"10.1371\/journal.pone.0064268","volume":"8","author":"MJ Larsen","year":"2013","unstructured":"Larsen MJ, Kruse TA, Tan Q, L\u00e6nkholm AV, Bak M, Lykkesfeldt AE et al (2013) Classifications within molecular subtypes enables identification of BRCA1\/BRCA2 mutation carriers by RNA tumor profiling. PLoS ONE 8:e64268. https:\/\/doi.org\/10.1371\/journal.pone.0064268","journal-title":"PLoS ONE"},{"key":"8011_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10549-014-3056-x","volume":"147","author":"A Prat","year":"2014","unstructured":"Prat A, Cruz C, Hoadley KA, D\u00edez O, Perou CM, Balma\u00f1a J (2014) Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Res Treat 147:185\u2013191. https:\/\/doi.org\/10.1007\/s10549-014-3056-x","journal-title":"Breast Cancer Res Treat"},{"key":"8011_CR18","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384:2394\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"key":"8011_CR19","unstructured":"AstraZeneca (2023) Highlights of prescribing information: LYNPARZA\u00ae (olaparib) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s028lbl.pdf. Accessed November 21, 2025"},{"key":"8011_CR20","unstructured":"European Medicines Agency (2024) Lynparza: EPAR - product information. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf. Accessed November 21, 2025"},{"key":"8011_CR21","doi-asserted-by":"publisher","first-page":"GS1-09","DOI":"10.1158\/1557-3265.SABCS24-GS1-09","volume":"31","author":"J Garber","year":"2025","unstructured":"Garber J, Cameron D, Campbell C, Yothers G, Taboada M, El-Abed S et al (2025) Abstract GS1-09: OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer. Clin Cancer Res 31:GS1-09. https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-GS1-09","journal-title":"Clin Cancer Res"},{"key":"8011_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","volume":"42","author":"I Bedrosian","year":"2024","unstructured":"Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S et al (2024) Germline testing in patients with breast cancer: ASCO\u2013Society of Surgical Oncology guideline. J Clin Oncol 42:584\u2013604. https:\/\/doi.org\/10.1200\/JCO.23.02225","journal-title":"J Clin Oncol"},{"key":"8011_CR23","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate V.2.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed November 21, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way"},{"key":"8011_CR24","unstructured":"Flatiron Health (2025) Database characterization guide. https:\/\/flatiron.com\/database-characterization. Accessed November 21, 2025"},{"key":"8011_CR25","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1200\/JCO.20.03613","volume":"39","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L et al (2021) Updated Standardized Definitions for Efficacy End Points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol 39:2720\u20132731. https:\/\/doi.org\/10.1200\/JCO.20.03613","journal-title":"J Clin Oncol"},{"key":"8011_CR26","unstructured":"US Food and Drug Administration (2021) FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer. Accessed November 21, 2025"},{"key":"8011_CR27","unstructured":"US Food and Drug Administration (2022) FDA approves olaparib for adjuvant treatment of high-risk early breast cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer. Accessed November 21, 2025"},{"key":"8011_CR28","doi-asserted-by":"publisher","first-page":"e","DOI":"10.61622\/rbgo\/2024rbgo29","volume":"46","author":"MFI Pereira","year":"2024","unstructured":"Pereira MFI, Buzatto IPC, Carrara HHA, Buono FO, de Andrade JM, Orlandini LF et al (2024) Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer. Rev Bras Ginecol Obstet 46:e-rbgo29. https:\/\/doi.org\/10.61622\/rbgo\/2024rbgo29","journal-title":"Rev Bras Ginecol Obstet"},{"key":"8011_CR29","doi-asserted-by":"publisher","first-page":"1152123","DOI":"10.3389\/fonc.2023.1152123","volume":"13","author":"FS Di Lisa","year":"2023","unstructured":"Di Lisa FS, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U et al (2023) Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study. Front Oncol 13:1152123. https:\/\/doi.org\/10.3389\/fonc.2023.1152123","journal-title":"Front Oncol"},{"key":"8011_CR30","doi-asserted-by":"crossref","unstructured":"Kim MJ, Kim HJ, Kim JY, Shin J, Park YH (2025) Effectiveness of adjuvant capecitabine in triple-negative breast cancer patients with residual disease after neoadjuvant treatment: a real-world evidence study in Korea. Clin Breast Cancer 25:e431\u2013e439.e4. https:\/\/doi.org\/10.1016\/j.clbc.2024.12.019","DOI":"10.1016\/j.clbc.2024.12.019"},{"key":"8011_CR31","doi-asserted-by":"crossref","unstructured":"Lynce F, Dow J, Sangli C, Zhao W, Berrocal-Almanza LC, Miranda M, et al (2024) P5-10-08: Real-world clinical outcomes of patients with HER2-negative BRCAm early breast cancer treated with adjuvant capecitabine. Presented at San Antonio Breast Cancer Symposium\u00ae (SABCS\u00ae) 2024. December 10\u201313, 2024, San Antonio, TX, USA","DOI":"10.1158\/1557-3265.SABCS24-P5-10-08"},{"key":"8011_CR32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","volume":"33","author":"FJ Couch","year":"2015","unstructured":"Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P et al (2015) Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 33:304\u2013311. https:\/\/doi.org\/10.1200\/JCO.2014.57.1414","journal-title":"J Clin Oncol"},{"key":"8011_CR33","doi-asserted-by":"publisher","first-page":"106736","DOI":"10.1016\/j.cct.2022.106736","volume":"116","author":"RS Tang","year":"2022","unstructured":"Tang RS, Zhu J, Chen TT, Liu F, Jiang X, Huang B et al (2022) Impact of COVID-19 pandemic on oncology clinical trial design, data collection and analysis. Contemp Clin Trials 116:106736. https:\/\/doi.org\/10.1016\/j.cct.2022.106736","journal-title":"Contemp Clin Trials"},{"key":"8011_CR34","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41416-024-02827-z","volume":"131","author":"B Arun","year":"2024","unstructured":"Arun B, Couch FJ, Abraham J, Tung N, Fasching PA (2024) BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. Br J Cancer 131:1400\u20131414. https:\/\/doi.org\/10.1038\/s41416-024-02827-z","journal-title":"Br J Cancer"},{"key":"8011_CR35","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","volume":"26","author":"ER Manahan","year":"2019","unstructured":"Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM et al (2019) Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol 26:3025\u20133031. https:\/\/doi.org\/10.1245\/s10434-019-07549-8","journal-title":"Ann Surg Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08011-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08011-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08011-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:49:13Z","timestamp":1787640553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08011-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8011"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08011-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As this study used deidentified patient records, ethics approval was not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study was noninterventional and used deidentified patient records, informed consent was not required.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data from this study were published in part in an abstract from the 2025 ASCO Annual Meeting. Lynce P, Ru M, Luo L, Miranda M, Xu X, Isaacs C (2025) J Clin Oncol. 43(16 suppl):e12503.","order":3,"name":"Ethics","label":"Prior publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Filipa Lynce has received grants\/contracts (to institution) from AstraZeneca, Gilead, Ideaya, Incyte, Merck, Zentalis, consulting fees from AstraZeneca and Pfizer, speaker fees\/honoraria from Gilead, has participated on an advisory board for AstraZeneca, and is Executive Officer for the Alliance Foundation Trials. Meng Ru, Linlin Luo, and Xiaoqing Xu are employees and stockholders of AstraZeneca.\u00a0Miguel Miranda is an employee of Amgen and was an employee and stockholder of AstraZeneca at the time of this analysis.\u00a0Claudine Isaacs has consulted for Arvinas, AstraZeneca, Genentech, Gilead, Merck, Novartis, Pfizer, PUMA, and Seattle Genetics, received royalties from McGraw Hill and Wolters Kluwer, received research support (to institution) from AstraZeneca, Bristol Myers Squibb, Genentech, Novartis, Pfizer, Regeneron, Seattle Genetics, and Tesaro\/GSK, and declares financial relationships with Medscape and MJH Holdings.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"41"}}